The Peptide CommonsEst. May 2024
Independent. We sell nothing and are affiliated with no manufacturer or pharmacy. Every moderation action is logged in public
Governance

Moderation log

Page 5 of 9.

  • Topic unlistedR8 s.leclerc12 January 2026ML10157
    Coming back to: Over-dilution: when your dose falls below one readable graduation

    Unlisted rather than closed. The topic is still readable and linkable, but it no longer appears in the lists because its first post has been superseded and the corrections are twenty posts down. A replacement topic with the corrected framing is linked from the top.

  • Topic closedR15 dr_okonkwo11 January 2026ML10064
    About the Other compounds category

    Closed at the author's request. They asked for it in the topic and there is no reason to refuse. The solution remains marked and the topic remains readable and searchable.

  • Title editedR7 t.vasquez10 January 2026ML10182
    The 2.5 mg starting dose is not a therapeutic dose — why that matters — a second dataset

    Retitled so that the title states the question. The original was a description of a feeling, which is a legitimate way to start a post and a poor way to be found in six months.

  • Account silencedR6 j.mwangi10 January 2026ML10106
    What a purity-only report leaves out

    Silenced for 72 hours after three hidden posts in a week, each citing R1, each after a direct request to change the framing rather than the argument. Silencing is a cooling-off measure and not a ban; posting resumes automatically. The member has been told exactly that.

  • Topic movedR8 dr_okonkwo3 January 2026ML10100
    Robustness: the parameters worth deliberately varying

    Moved to the regional subcategory. The answer is country-specific and leaving it in a general category invites people to generalise from it, which is exactly what the regional categories exist to prevent.

  • Topic unlistedR8 s.leclerc2 January 2026ML10163
    Tracking a preprint to publication: a worked example

    Unlisted pending a response from the author about the batch and method behind the claim in the first post. If those arrive it will be relisted immediately. Under R6 this is the least destructive option available.

  • Topic closedR15 dr_okonkwo2 January 2026ML10051
    Tirzepatide in type 2 diabetes: the SURPASS programme, summarised honestly — the long…

    Closed. The topic has been superseded by a maintained document that now covers the same ground with citations and a review date. The document links back here and this topic links forward. Neither is deleted.

  • Topic closedR11 KLindqvist28 December 2025ML10072
    DXA precision and the least significant change for lean mass

    Closed under R15. The topic re-litigated a decision already answered in Meta, without new argument. The earlier answer is linked from the first post.

  • Post hidden by flagR12 hana.sato21 December 2025ML10012
    Airline travel with a temperature-sensitive injectable — what changed since

    Hidden under R6. The reply escalated a documented discrepancy on one lot into a general accusation about the supplier. The underlying report is good and is now recorded on the vendor documentation page; the accusation is not supported by it.

  • Title editedR8 s.leclerc16 December 2025ML10172
    Managing an unplanned gap in supply — what changed since

    Retitled to remove an inaccurate compound name. The topic is about a different molecule than the title claimed, and search results were sending people to the wrong place.

  • Topic movedR8 mira.patel6 December 2025ML10089
    Revisiting: Aggregates and why a purity assay may miss them entirely

    Moved because the specialists who can answer this read the destination subcategory and not the origin. No criticism of the choice — the categories on this site are not obvious from outside and getting this wrong is expected.

  • Post hidden by flagR1 t.vasquez6 December 2025ML10035
    Second pass at: Journal club: STEP 4 and what a withdrawal design can prove

    Two flags, both from members in good standing, both citing the tone rather than the claim. On reading it I agree: the argument was sound and the framing was contemptuous. Hidden under R1 with a note asking for the same point without the last sentence. The author has already reposted it and it is better.

  • Topic unlistedR6 j.mwangi3 December 2025ML10158
    Compounds this community declines to help with, and why

    Unlisted rather than closed. The topic is still readable and linkable, but it no longer appears in the lists because its first post has been superseded and the corrections are twenty posts down. A replacement topic with the corrected framing is linked from the top.

  • Topic closedR15 t.vasquez2 December 2025ML10042
    Micronutrient adequacy at low total intake — does this still hold?

    Closed. The topic has been superseded by a maintained document that now covers the same ground with citations and a review date. The document links back here and this topic links forward. Neither is deleted.

  • Hidden post restoredR1 owen.brady30 November 2025ML10192
    Second pass at: Journal club: STEP 4 and what a withdrawal design can prove

    Restored. The author supplied the batch number, the test date, the method and the report, which is precisely what R6 asks for. The original hiding was correct on the information available and is wrong now, so the post is back where it was.

  • Topic movedR7 s.leclerc19 November 2025ML10079
    A preprint whose numbers changed substantially at publication

    Moved into Safety at the request of a clinician in the topic. That is the correct escalation and it does not require a moderator to agree first.

  • Post hidden by flagR1 dr_okonkwo15 November 2025ML10000
    Second pass at: Journal club: STEP 4 and what a withdrawal design can prove

    Three community flags on a single reply, all citing an allegation without supporting documentation. The post named a supplier and asserted deliberate substitution with no batch, date, method or document attached. Hidden under R6. I have told the author in the topic that a report containing those four things is welcome and will be restored in place.

  • Topic closedR15 t.vasquez13 November 2025ML10046
    Deconvolution of a multiply charged envelope

    Auto-closed after the configured interval with no reply. Nothing wrong with the topic; the platform closes quiet topics so that a two-year-old answer does not attract a new question underneath it. Anyone with a follow-up should open a new topic and link back.

  • Account silencedR1 KLindqvist8 November 2025ML10111
    A preprint whose numbers changed substantially at publication

    Silenced for 48 hours. Six replies in one evening escalating a disagreement that another member had already de-escalated twice. Both parties were asked to stop; only one did. The other party's conduct was fine and is not recorded here.

  • Topic unlistedR11 owen.brady29 October 2025ML10165
    Washout: how long is long enough, and for what purpose

    Unlisted at the request of two clinicians in the topic, who considered the first post likely to be read as instruction. R11. The subsequent discussion is careful and is worth keeping accessible.

  • Topic movedR8 t.vasquez25 October 2025ML10080
    What a 2 ppm match establishes, and what it does not

    Moved to the regional subcategory. The answer is country-specific and leaving it in a general category invites people to generalise from it, which is exactly what the regional categories exist to prevent.

  • Topic closedR8 mira.patel24 October 2025ML10057
    Criticising the method without criticising the authors — one year on

    Auto-closed after the configured interval with no reply. Nothing wrong with the topic; the platform closes quiet topics so that a two-year-old answer does not attract a new question underneath it. Anyone with a follow-up should open a new topic and link back.

  • Topic closedR1 s.leclerc23 October 2025ML10056
    Micronutrient status when intake falls substantially

    Closed after the last two exchanges stopped being about the question and started being about each other. Both members have been asked to continue in Meta if they want the disagreement adjudicated. The technical content above the line stands and is worth reading.

  • Account silencedR15 dr_okonkwo20 October 2025ML10117
    Payment method and the leverage it gives you, ranked

    Silence lifted early at the member's request after they acknowledged the R1 problem in Meta and rewrote the post. Recording the reversal because a log that only records punishments is not a log.

  • Account silencedR15 dr_okonkwo11 October 2025ML10128
    Payment method and the leverage it gives you, ranked

    Silenced for 48 hours. Six replies in one evening escalating a disagreement that another member had already de-escalated twice. Both parties were asked to stop; only one did. The other party's conduct was fine and is not recorded here.